WHO says governments must do more to improve access to essential medicines

Cancer researchers at the Max Delbr?nter for Molecular Medicine (MDC) Berlin-Buch and the Charité - Universit? Medizin Berlin (Germany) have identified a gene which enables them to predict for the first time with high probability if colon cancer is going to metastasize. Assistant Professor Dr. Ulrike Stein, Professor Peter M. Schlag, and Professor Walter Birchmeier

Full Post: Scientists find gene that is a powerful predictor of colon cancer metastasis

An alarming lack of availability of essential medicines in the public sector drives patients to pay higher prices in the private sector or go without, according to a WHO study reported in the online edition of The Lancet. The results confirm that governments must do more to improve access to essential medicines as part of their efforts to make national health systems more efficient and equitable.

The study analysed data from surveys in 36 countries from all WHO geographical regions and World Bank income groups. Results show an average public-sector availability of only 38% across surveys. This forces patients to buy medicines from the private sector where treatments are more expensive and frequently unaffordable. In Africa, for example, the lowest-paid government worker needs to spend two days’ salary each month to purchase diabetes treatment using the lowest-priced generic medicine. When the originator brand is used, costs escalate to over eight days’ wages.

“You should not have to choose between buying medication for an ailing parent or buying food for your children,” said Carissa Etienne, WHO Assistant Director-General of Health Systems and Services. “It is not fair or necessary. That is why we are calling again for comprehensive primary health care, so that health systems in every country put the real health needs of people and communities first, and families are not impoverished or bankrupted because of health care payments.”

On the pricing side, the study revealed that “cuts” taken by wholesalers, distributors and retailers plus government taxes and duties are driving prices beyond affordability in many countries. In some countries, add-on costs can double the public-sector price of medicine, while in the private sector, wholesale mark-ups ranged from 2% to 380%, and retail mark-ups ranged from 10% to 552%.

“Essentially, multi-layered supply chain costs add up to one thing for patients, no access to essential medicines,” said Dr Richard Laing of the Essential Medicines and Pharmaceutical Policies department at WHO. “When you pull apart the layers of additional charges, the potential solutions for governments to make life-saving medicines more available and accessible are clear - improve financing and distribution efficiency, promote the use of generic products and control supply chain costs by limiting mark-ups and removing duties and taxes.”

The study further asserts that these actions should all be part of national medicine policies that are measured and evaluated against predetermined benchmarks at least every two years, with routine monitoring and reporting more frequently.

The results cover 15 medicines included in at least 80% of surveys, as well as four specific medicines used to treat asthma, diabetes, hypertension and acute infections. The figures are adjusted to account for differences in buying power of local currencies and then compared to international reference prices, allowing for cross-country comparison.

The work is part of an ongoing joint effort between WHO and Health Action International (HAI) to highlight and improve availability and affordability of essential medicines, especially in low- and middle-income countries.



A provocative debate in this week’s PLoS Medicine examines whether the private sector should step up its involvement in delivering health care in low-income countries. These countries suffer a disproportionate burden of disease, and often struggle with weak health systems. Both the public and private sector deliver health care in these countries, but the appropriate

Full Post: Should the private sector play a greater role in delivering health care in low-income countries?

Just like saving money on groceries or finding the best deal on gas, smart consumers can cut their prescription drug costs with just a little bit of work, say pharmacists at the University of North Carolina at Chapel Hill. Stefanie Ferreri, Pharm.D., and Jena Ivey, Pharm.D., both practicing pharmacists and clinical assistant professors at the

Full Post: Good advice to cut prescription drug costs

A declaration by the World Health Organization (WHO) could raise the profile of traditional or alternative health treatments such as acupuncture and herbal medicine. The WHO has called on member countries to integrate traditional medicine (TM) into their national health systems and for countries to share experience and information related to national policy, regulation, research,

Full Post: Alternative health treatments get a boost from WHO

According to a new report more Australian privately insured patients used the public hospital system last year than previously and there are concerns that encouraging people to take out private health insurance is doing little to reduce the burden on the public health system. According to the report by the Private Health Insurance Administration Council

Full Post: More private patients in public Australian hospital beds

The government needs to rethink its approach to NHS reforms, says UNISON, in the wake of a new damning report on the cost of commissioning and outsourcing. It should concentrate on giving NHS patients the care they need - and value for money - rather than using reforms to outsource services and ‘throw precious money

Full Post: Rethink urged on NHS outsourcing